Navigation Links
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Date:6/11/2009

<24 months; and 3) a single dose of Prevenar 13 at age 24 to <72 months. Each of the 3 regimens was shown to elicit immune response levels against all 13 serotypes that were either comparable to or greater than the IgG antibody concentrations achieved in infants after a 3-dose infant series and to have acceptable tolerability and safety profiles.

Overall, the most frequently reported adverse events in the Phase 3 trials included injection site reactions, (redness, swelling, and tenderness), fever (greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea and rash.

Health Economic Models

Three health economic models presented at ESPID estimated the potential public health and economic impact of Prevenar 13. The results of the analyses in the Netherlands, the UK, and Germany and the US suggested that the introduction of Prevenar 13, if approved, to national immunization programs has the potential to further reduce PD levels in children who are vaccinated as well as in the unvaccinated population (through a herd effect). Based on these economic models, the researchers estimated that routine vaccination with Prevenar 13 could be cost effective or cost saving.

Registration Status

To date, Wyeth has submitted regulatory applications for the pediatric use of Prevenar 13 in more than 45 countries. In December 2008, Wyeth submitted a marketing authorization application (MAA) for Prevenar 13 to the European Medicines Agency (EMEA). In March 2009, Wyeth submitted a Biologic License Application (BLA) for Prevenar 13 to the U.S. Food and Drug Administration (FDA). Last month, the FDA granted the BLA priority review -- a designation given to products that, if approved, would be a significant therapeutic or public health advance. Prevenar 13 is also being studied in
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... Diego, CA (PRWEB) , ... July 24, 2015 , ... ... & Referral Center in support of stem cell therapy training and clinical opportunities. , ... this new opportunity to veterinarians in the San Diego area. Stem cell therapy is ...
(Date:7/24/2015)... Origin Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), ... , today announced that the Company will report results ... 2015, before the market opens on Wednesday, August 5th, 2015. ... 5th, 2015, at 9:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial the following numbers approximately ...
(Date:7/23/2015)... ANGELES , July 23, 2015 ImmunoCellular Therapeutics, ... to report financial results for the second quarter 2015 on ... a conference call and webcast on that day at 5:00 ... and provide a business update. The call will be hosted ...   , , , LIVE CALL: ...
(Date:7/23/2015)... , July 23, 2015 The Hong Kong ... given the prestigious accolade of "Most Innovative Technology ... world-class position in fostering innovation and technology development ... region.  The award has ... innovation and technology magazine and website with a ...
Breaking Biology Technology:VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 2HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 3
... 6 VIRxSYS Corporation announced today the publication ... Abundant Albumin Transcripts for Production of Therapeutic Proteins In ... The study describes a novel RNA therapy technique in which ... gene "hijacks" the albumin, causing it to produce the newly ...
... 6 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... has posted a new entry on his blog on ... recent meetings in Zurich, Switzerland, further development plans for ... for clinical-grade Oxycyte, and plans for raising additional capital. ...
... April 6 /PRNewswire/ - Orcrist Bio Inc. (ORC) ... today the approval of its Phase I, open-label, ... volunteers, by the European Competent Authority in Seville, ... assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction ...
Cached Biology Technology:VIRxSYS Publishes New Study on RNA Therapy 2Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750 2
(Date:7/21/2015)... 2015 Today, ZTE announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1025 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... manufacturer in China and we are proud ... 5 for Axon , its first ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... release is available in German . ... in Freiburg have gained important insights for stem cell research ... to the development of new treatments. As Rolf Kemler,s research ... determines the length of the telomeres and a signalling pathway ...
... , Akron, Ohio, June 27, 2012 Expertise in fluid ... a new research center designed to help physicians better diagnose ... neck and shoulders. Chiari malformation is a disorder of ... brain and spinal fluid. UA engineers are able to ...
... animal scientists are working together to meet the challenges of ... experimental Biology on 28th June will demonstrate innovative techniques and ... issues, crop yields and diminishing fish stocks. , In ... the world,s four most important crops has fallen short of ...
Cached Biology News:When does a headache need an engineer to fix it? 2When does a headache need an engineer to fix it? 3
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... offers a large collection of phage ... tissuea, cell lines, and mouse tissues. ... pHD9 vector. The size of cDNA ... from 200bp to 1000bp by gel ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
7G10 anti-Fasciclin III...
Biology Products: